Edition:
United Kingdom

Nestle SA (NESN.S)

NESN.S on Virt-X Level 1

75.76CHF
23 Feb 2018
Change (% chg)

CHF0.16 (+0.21%)
Prev Close
CHF75.60
Open
CHF75.44
Day's High
CHF75.94
Day's Low
CHF75.14
Volume
5,855,971
Avg. Vol
6,038,782
52-wk High
CHF86.40
52-wk Low
CHF73.80

Latest Key Developments (Source: Significant Developments)

Nestlé Nominates Three New Independent Directors To Board
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Nestle SA ::NESTLÉ NOMINATES THREE NEW INDEPENDENT DIRECTORS TO BOARD.PROPOSES PABLO ISLA, CEO OF INDITEX TO BOARD ​.BOARD ALSO PROPOSES INDIVIDUAL RE-ELECTION OF CHAIRMAN AND OTHER CURRENT MEMBERS OF BOARD.PROPOSES PABLO ISLA, CEO OF INDITEX, KASPER RORSTED, CEO OF ADIDAS, AND KIMBERLY ROSS, FORMER CFO OF BAKER HUGHES, FOR ELECTION TO ITS BOARD.WITH PROPOSED NOMINEES FULL NESTLÉ BOARD WILL COMPRISE 14 MEMBERS, OF WHICH 12 ARE INDEPENDENT DIRECTORS.THREE CURRENT DIRECTORS, ANDREAS KOOPMANN, STEVEN G. HOCH, AND NAÏNA LAL KIDWAI WILL RETIRE FROM BOARD AT AGM ON APRIL 12, 2018.ELECTIONS WILL TAKE PLACE AT COMPANY'S ANNUAL GENERAL MEETING ON APRIL 12, 2018.  Full Article

Ferrero Says To Acquire Nestlé's Manufacturing Facilities In Bloomington, Franklin Park & Itasca
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Ferrero Group: :FERRERO - TO ACQUIRE NESTLÉ'S U.S. MANUFACTURING FACILITIES IN BLOOMINGTON, FRANKLIN PARK AND ITASCA, ILLINOIS.FERRERO GROUP SAYS TO ACQUIRE MORE THAN 20 AMERICAN BRANDS, INCLUDING BRANDS SUCH AS BUTTERFINGER, BABYRUTH, 100GRAND, RAISINETS, WONKA.  Full Article

Nestlé To Sell U.S. Confectionery Business To Ferrero For $2.8 Bln
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - NESTLÉ SA ::PRESS RELEASE - NESTLÉ AGREES TO SELL U.S. CONFECTIONERY BUSINESS TO FERRERO.ANNOUNCED THAT IT AGREED TO SELL ITS U.S. CONFECTIONERY BUSINESS TO FERRERO FOR USD 2.8 BILLION IN CASH.TRANSACTION COVERS U.S.-FOCUSED CONFECTIONERY BRANDS ONLY AND DOES NOT INCLUDE NESTLÉ'S TOLL HOUSE BAKING PRODUCTS.NESTLÉ'S U.S. CONFECTIONERY BUSINESS REPRESENTS ABOUT THREE PERCENT OF U.S. NESTLÉ GROUP SALES.SAYS "MOVE ALLOWS NESTLÉ TO INVEST AND INNOVATE ACROSS A RANGE OF CATEGORIES WHERE WE SEE STRONG FUTURE GROWTH".  Full Article

Nestle exec says Atrium will add to earnings immediately
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Nestle Sa ::NESTLE EXEC SAYS ATRIUM INNOVATION ACQUISITION WILL ADD TO EARNINGS.NESTLE EXEC SAYS 80 PERCENT OF ATRIUM'S FOOTPRINT IS IN USA.NESTLE EXEC SAYS ATRIUM HAS BEEN GROWING AT A DOUBLE DIGIT RATE AND WILL CONTINUE TO DO SO.  Full Article

Nestle close to buying Atrium Innovations for about $2.3 bln - WSJ
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - :NESTLE CLOSE TO BUYING ATRIUM INNOVATIONS FOR ABOUT $2.3 BILLION - WSJ.  Full Article

Nestle is among potential suitors for Hain Celestial - Bloomberg
Monday, 20 Nov 2017 

Nov 20 (Reuters) - :Nestle is among potential suitors for Hain Celestial - Bloomberg, citing sources.Nestle has held preliminary talks about purchasing all or parts of Hain Celestial - Bloomberg, citing sources.  Full Article

Nestle among potential bidders for Hain Celestial- CNBC
Monday, 20 Nov 2017 

Nov 20 (Reuters) - :Nestle among potential bidders for Hain Celestial- CNBC, citing report‍​.  Full Article

Galderma reports FDA approval of restylane silk
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Nestle SA ::Galderma announces FDA approval of restylane® silk as the first ha dermal filler approved for injection via cannula.Galderma - received U.S. Food and drug administration approval for use of a small blunt tip cannula with restylane silk for lip augmentation​.  Full Article

Codexis Inc, Nestlé Health Science enter strategic collaboration​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Codexis Inc :Codexis Inc - ‍co, Nestlé Health Science enter strategic collaboration​.Codexis Inc - ‍Codexis receives an upfront payment of $14 million and potential milestones and royalties depending on product success for deal​.Codexis Inc - deal ‍includes an option for global development of CDX-6114 for PKU​.Codexis Inc - ‍Codexis will be responsible for clinical development costs for CDX-6114 up to and including Phase 1 in healthy volunteers​.Codexis - after ‍phase 1, Nestlé health science will have option to obtain exclusive global license to CDX-6114.Codexis - after ‍Phase 1, Nestlé health science will be responsible for all future development and commercialization of CDX-6114​.  Full Article

Nestle has no comment on Pfizer's consumer healthcare business
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Nestle SA :Nestle declines comment on any interest in Pfizer's consumer healthcare business, says does not comment on rumours as a matter of policy.  Full Article

Photo

General Mills moves into pet food with $8 billion Blue Buffalo deal

Cheerios cereal maker General Mills Inc will buy Blue Buffalo Pet Products Inc for nearly $8 billion, foraying into a fast-growing pet food market to counter declining sales of processed foods. | Video